Novartis has completed its acquisition of Xiidra (lifitegrast ophthalmic solution) 5%, the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease.
Xiidra is a prescription eye drop solution designed to treat the signs and symptoms of dry eye disease.
It is approved to treat signs and symptoms of dry eye disease in multiple markets including the US, Canada and Australia.
It is under regulatory review in a number of additional markets.
“This deal delivers on our ongoing commitment to reimagine medicine for patients suffering from a variety of eye diseases, while also laying critical groundwork for future, potential front-of-the-eye pipeline products we have in development,” said Marie-France Tschudin, President of Novartis Pharmaceuticals.